Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing innovative small molecule immunotherapies in oncology, is proud to report preliminary data from a Phase 2 clinical trial of their lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs), specifically thymoma and thymic carcinoma.
The study is being conducted in collaboration with the National Cancer Institute (NCI), a division of the National Institutes of Health. The data has been made available in an abstract for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, setting a powerful example of progress in the global fight against cancer.
At Promontory Therapeutics, we are thrilled to have the opportunity to continue our collaboration with the NCI to bring a potential treatment option to patients with relapsed TETs. Preliminary data to date suggests that PT-112 is safe, tolerable, and clinically active, and initial translational evidence of its immune activation is an exciting and promising development. We look forward to further exploring the potential of this promising therapy.
The Phase 2 clinical trial with the NCI is an exciting opportunity to assess thesafety and tolerability of PT-112 in patients with thymoma and thymic carcinoma, as well as explore its ability to activate and enhance immune cell infiltration in response to treatment. Through NCI’s immuno-profiling capabilities, this trial is sure to make an impressive impact on treatment and outcomes for these malignancies.
Promontory is providing NCI with PT-112 drug supply and support for correlative research, and NCI is overseeing enrollment and treatment of the clinical trial’s intended 53 patients.
PT-112 is an exciting new small-molecule conjugate targeting oncology, and its unique mechanism of action is revolutionizing the way we approach cancer treatments. Its ability to induce immunogenic cell death (ICD) through the release of damage associated molecular patterns (DAMPs) which bind to dendritic cells and attract downstream immune effector cells, creates a more robust anti-tumor response.
Its osteotropism also allows PT-112 to reach its highest concentrations in certain areas of the bone, enabling it to effectively treat cancers that originate or metastasize there. Human studies of PT-112 have already demonstrated an encouraging safety profile and significant, long-lasting responses in heavily pre-treated patients. Further, Phase 1b and Phase 2a studies in solid tumors and NSCLC, respectively, have been presented at ESMO, and a Phase 1 study in relapsed or refractory multiple myeloma patients recently appeared at ASH 2020. To maximize its potential, PT-112 monotherapy Phase 2 development is underway in mCRPC, further supported by a CRADA with the NCI for a proof of concept Phase 2 study in thymic epithelial tumors.
About Promontory Therapeutics
Promontory Therapeutics Inc., a clinical stage pharmaceutical company, has developed the first small molecule conjugate of pyrophosphate in oncology – PT-112. Through its unique mechanism of action, PT-112 triggers immunogenic cell death (ICD) through the release of damage associated molecular patterns (DAMPs) which activate anti-cancer immune responses in the tumor microenvironment.
Three Phase 1 clinical studies have shown single-agent and combination anti-cancer activity with good tolerability, and two Phase 2 studies of PT-112 are ongoing. Through collaborations with Pfizer and Merck KGaA (EMD Serono in the US and Canada), a clinical study of PT-112 with the PD-L1 inhibitor avelumab is now completed. Moreover, the NCI’s Phase 2 trial of PT-112 in thymic epithelial tumors has been granted with Orphan Drug designation. Through research and development activities conducted in the US, Europe, and Asia, Promontory Therapeutics is contributing to the fight against cancer.